Review
Copyright ©The Author(s) 2021.
World J Gastroenterol. Aug 21, 2021; 27(31): 5152-5170
Published online Aug 21, 2021. doi: 10.3748/wjg.v27.i31.5152
Table 1 Major features of the eight trials examining for histological parameters
Ref.
Study arm, n
Follow-up, yr
Medication
Methods
Histologic parameter
Eradicated
Not eradicated
1 = OS
AG
IM
2 = RCTAntrum
Corpus
Antrum
Corpus
Before
After
P value
Before
After
P value
Before
After
P value
Before
After
P value
Sung et al[34]2262451OAC20.64 ± 0.780.70 ± 0.82P = 0.6270.06 ± 0.310.02 ± 0.18P = 0.6820.78 ± 0.980.61 ± 0.94P = 0.0140.04 ± 0.320.06 ± 0.30P = 0.391
Annibale et al[39]2570.5BAM10.56 ± 0.240.5 ± 0.2NS1.64 ± 0.111.36 ± 0.18NS0.58 ± 0.25 0.53 ± 0.23NS0.52 ± 0.130.76 ± 0.16NS
Ohkusa et al[40]115481-1.25PPI/A/C10.8 ± 1At 1–3 mo: 0.8 ± 1P > 0.20.5 ± 0 At 1–3 mo: 0.3 ± 0 P = 0.0200.7 ± 0At 1–3 mo: 0.6 ± 0P = 0.140.0 ± 0.0At 1–3 mo: 0.2 ± 0P = 0.022
At 12–15 mo: 0.9 ± 1P = 0.15At 12–15 mo: 0.2 ± 0 P = 0.001At 12–15 mo: 0.4 ± 0P < 0.001At 12–15 mo: 0.1 ± 0P > 0.2
Lu et al[33]92623O/LAC11.25 ± 0.44 0.97 ± 0.83P < 0.01NANANA0.64 ± 0.760.73 ± 0.77 NSNANANA
Kang et al[41]210163PPI/A/C10.85 ± 0.06 1 yr: 0.83 ± 0.06NS0.70 ± 0.07 1 yr: 0.42 ± 0.06P < 0.0010.91 ± 0.07 1 yr: 0.83 ± 0.06 NS0.60 ± 0.071 yr: 0.54 ± 0.06NS
54163PPI/A/C10.96 ± 0.14 3 yr: 1.32 ± 0.20 NS0.91 ± 0.203 yr: 0.45 ± 0.15P = 0.0331.02 ± 0.14 3 yr: 1.29 ± 0.14 NS0.68 ± 0.153 yr: 0.83 ± 0.14 NS
Kodama et al[42]118218.6PPI/A/C11.60 ± 0.09 1.02 ± 0.08P < 0.0010.71 ± 0.10 0.02 ± 0.02P < 0.0010.60 ± 0.110.43 ± 0.09NS0.17 ± 0.120.00 ± 0.00P < 0.05
Kodama et al[43]1762110PPI/A/C1AI: 1.39 ± 0.076 yr: 0.90 ± 0.09P < 0.05B1: 1.08 ± 0.08 1 yr: 0.78 ± 0.11P < 0.05A1: 1.14 ± 0.10NANSB1: 0.97 ± 0.096y: 0.42 ± 0.17P < 0.05
A2: 1.39 ± 0.061 yr: 1.06 ± 0.08P < 0.01B2: 0.52 ± 0.060.6 mo: 0.29 ± 0.07P < 0.05A2: 0.50 ± 0.07NANSB2: 0.13 ± 0.04 NANS
IA: 1.51 ± 0.081 yr: 1.24 ± 0.09P < 0.05A1: 1.04 ± 0.09 NANS
Hwang et al[44]4429110PPI/A/C E/A/C/M1n = 178n = 89 (50.0) P = 0.002n = 105n = 72 (68.8)P = 0.01n = 221n = 45 (20.4)P = 0.002n = 142n = 31 (21.8)P = 0.01
Table 2 Major features of five meta-analyses
Ref.
Year
Total No. of study
Eradication group
Control group
OR/RR
95%Cl
Total No.
Total events
Incidence rate
Total No.
Total events
Incidence rate
Sugimoto et al[118]20204RCTs2731732.7%2733491.80%0.670.47–0.96
Sugano et al[119]201932163013161.90%148055353.60%0.460.39-0.55
Doorakkers et al[120]20168 Cohort128991190.90%186542081.10%0.460.32-0.66
Chen et al[121]20168RCTs3992741.90%39621162.90%0.640.48-0.85
Ford et al[104]20146RCTs3294511.60%3203762.40%0.660.46-0.95
Table 3 Studies on gastric microbiota alteration after eradication
Ref.
Year
Total subjects
Follow-up time
Age
Regimen
Study group
Main outcomes
1 = Adults
1 = TT for 7-14 d
HEG
H. pylori (-)
2 = Children
2 = QT for 10-14 d
Li et al[93]201733Day 0 and week 9111716Bacterial diversity increased and the relative abundance of Helicobacter decreased, while the relative abundance of other phyla increased
Serrano et al[99] 201916Day 0 and month 221115Bacterial diversity increased and the structures of the uninfected group were restored
Guo et al[98] 2020164Day 0 and month 61211549Bacterial diversity returned to the level of the control group. The structure of the bacteria was different after treatment compared to the control group. Microbiota functional capacities were changed
He et al[86]201917Weeks 0, 6, and 261210NABacterial diversity increased and structure and microbiota functional capacities were changed
Miao et al[82]202055Day 0 and week 421, 2 and STP 118Diversity was similar compared to the control group. The bacterial structure became close to controls
Sung et al[35]2020102Day 0 and 1 year11102NABacterial diversity increased and structure was changed